"Phase II Study of VIPER Chemotherapy in Rel/Ref DLBCL"

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

February 17, 2012

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

bortezomib, dexamethasone, ifosfamide

"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"

DRUG

mesna, cisplatin, etoposide, rituximab

"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"

Trial Locations (1)

10021

Weill Cornell Medical College, New York

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT00504751 - "Phase II Study of VIPER Chemotherapy in Rel/Ref DLBCL" | Biotech Hunter | Biotech Hunter